5PSQ-085 Metabolic disorders in patients treated with second-generation antipsychotics: an opportunity for pharmaceutical intervention

Abstract

Material and methods First, QI were selected through a literature review and expert meetings within the network for healthcare institutions (Zorgnet-ICURO). Next, these QIs were assessed for content validity in two separate datasets. The first dataset was obtained from national RD (year 2017, collected from all Belgian health care insurers). The second dataset comprised facturation data (FD) from two test hospitals: one general hospital psychiatry ward (GHP) and one mental health hospital (MHH). Results Four QIs were selected allowing in-depth evaluation of BZD use (Table ). For the MHH, reimbursement data corresponded well with local facturation data (719 vs. 710 patients with !1 BZD use) but not in the GHP (161 vs. 206 patients). Upon analysis, it emerged that three-quarters of QIs could not be calculated as RD does not provide for a valid nominator at different times during hospitalisation. A subsequent survey among hospitals showed high variability in how RD are reported to insurers, explaining information loss.